Author:
Smith Kenneth J.,Wateska Angela R.,Nowalk Mary Patricia,Lin Chyongchiou J.,Harrison Lee H.,Schaffner William,Zimmerman Richard K.
Subject
Public Health, Environmental and Occupational Health,Epidemiology
Reference32 articles.
1. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
2. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP);Nuorti;MMWR Recomm Rep,2010
3. Impact of PCV13 on invasive pneumococcal disease (IPD) burden and the serotype distribution in the U.S.;Pilishvili,2018
4. Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-United States;Ahmed;Clin Infect Dis,2020
5. Overview of three economic analyses of pneumococcal vaccinations at age 65;Leidner,2019
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献